The adverse inflammatory response of tobacco smoking in COVID-19 patients: biomarkers from proteomics and metabolomics
文献类型：期刊论文
| 作者 | Cui, Tenglong; Miao, Gan; Jin, Xiaoting; Yu, Haiyi; Zhang, Ze; Xu, Liting; Wu, Yili; Qu, Guangbo ; Liu, Guoliang; Zheng, Yuxin
|
| 刊名 | JOURNAL OF BREATH RESEARCH
 |
| 出版日期 | 2022 |
| 卷号 | 16期号:4页码:46002-1-11 |
| 关键词 | smoking COVID-19 biomarkers proteomics metabolomics |
| ISSN号 | 1752-7155 |
| 英文摘要 | Whether tobacco smoking affects the occurrence and development of coronavirus disease 2019 (COVID-19) is still a controversial issue, and potential biomarkers to predict the adverse outcomes of smoking in the progression of COVID-19 patients have not yet been elucidated. To further uncover their linkage and explore the effective biomarkers, three proteomics and metabolomics databases (i.e. smoking status, COVID-19 status, and basic information of population) from human serum proteomic and metabolomic levels were established by literature search. Bioinformatics analysis was then performed to analyze the interactions of proteins or metabolites among the above three databases and their biological effects. Potential confounding factors (age, body mass index (BMI), and gender) were controlled to improve the reliability. The obtained data indicated that smoking may increase the relative risk of conversion from non-severe to severe COVID-19 patients by inducing the dysfunctional immune response. Seven interacting proteins (C8A, LBP, FCN2, CRP, SAA1, SAA2, and VTN) were found to promote the deterioration of COVID-19 by stimulating the complement pathway and macrophage phagocytosis as well as inhibiting the associated negative regulatory pathways, which can be biomarkers to reflect and predict adverse outcomes in smoking COVID-19 patients. Three crucial pathways related to immunity and inflammation, including tryptophan, arginine, and glycerophospholipid metabolism, were considered to affect the effect of smoking on the adverse outcomes of COVID-19 patients. Our study provides novel evidence and corresponding biomarkers as potential predictors of severe disease progression in smoking COVID-19 patients, which is of great significance for preventing further deterioration in these patients. |
| 源URL | [https://ir.rcees.ac.cn/handle/311016/48518]  |
| 专题 | 生态环境研究中心_环境化学与生态毒理学国家重点实验室 |
| 作者单位 | 1.Chinese Academy of Medical Sciences - Peking Union Medical College 2.Qingdao University 3.Chinese Academy of Sciences 4.Research Center for Eco-Environmental Sciences (RCEES) 5.China-Japan Friendship Hospital 6.University of Chinese Academy of Sciences, CAS |
| 推荐引用方式 GB/T 7714 | Cui, Tenglong,Miao, Gan,Jin, Xiaoting,et al. The adverse inflammatory response of tobacco smoking in COVID-19 patients: biomarkers from proteomics and metabolomics[J]. JOURNAL OF BREATH RESEARCH,2022,16(4):46002-1-11. |
| APA | Cui, Tenglong.,Miao, Gan.,Jin, Xiaoting.,Yu, Haiyi.,Zhang, Ze.,...&Jiang, Guibin.(2022).The adverse inflammatory response of tobacco smoking in COVID-19 patients: biomarkers from proteomics and metabolomics.JOURNAL OF BREATH RESEARCH,16(4),46002-1-11. |
| MLA | Cui, Tenglong,et al."The adverse inflammatory response of tobacco smoking in COVID-19 patients: biomarkers from proteomics and metabolomics".JOURNAL OF BREATH RESEARCH 16.4(2022):46002-1-11. |
入库方式： OAI收割
来源：生态环境研究中心
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。